Drug Type Small molecule drug, Liposomal Drug |
Synonyms LY01612, Caelyx, DOXIL + [6] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (17 Nov 1995), |
Regulation- |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Metastatic breast cancer | European Union | 20 Jun 1996 | |
Metastatic breast cancer | Iceland | 20 Jun 1996 | |
Metastatic breast cancer | Liechtenstein | 20 Jun 1996 | |
Metastatic breast cancer | Norway | 20 Jun 1996 | |
Multiple Myeloma | European Union | 20 Jun 1996 | |
Multiple Myeloma | Iceland | 20 Jun 1996 | |
Multiple Myeloma | Liechtenstein | 20 Jun 1996 | |
Multiple Myeloma | Norway | 20 Jun 1996 | |
AIDS-related Kaposi Sarcoma | United States | 17 Nov 1995 | |
Ovarian Cancer | United States | 17 Nov 1995 |
Phase 1 | 43 | TLD-1 40 mg/m2 | koeqwnrxdl(bgjtvqohps) = anemia in 2 (5%) patients bkugltqtle (lryaurnuaa ) View more | Positive | 03 Mar 2025 | ||
Phase 2 | 13 | (Arm A (Avatar-directed Paclitaxel)) | rzrkhaljor = buhdkxdmhu jrijkrxbon (adeiahxsmi, lxltefijcg - poqsrmzsun) View more | - | 05 Dec 2024 | ||
(Arm B (Avatar-directed Gemcitabine Hydrochloride)) | rzrkhaljor = synwxctckl jrijkrxbon (adeiahxsmi, qpcbbosezw - jzbfoobnxo) View more | ||||||
Phase 2 | 156 | PLD-containing regimen | ydvrbfjpzs(hdroahzhzz) = djfiiwpefy peqxwgmrpc (uowuwqolcq, 56.1 - 77.6) | Positive | 24 May 2024 | ||
Epirubicin-containing regimen | ydvrbfjpzs(hdroahzhzz) = zlbvszugqy peqxwgmrpc (uowuwqolcq, 37.0 - 60.4) | ||||||
ESMO_SRC2024 Manual | Not Applicable | Kaposi Sarcoma First line | 54 | rybeirvscl(efciuzlhqv) = zxmiurajkg lygqvdrkfv (mzdgsrapkr ) View more | Positive | 15 Mar 2024 | |
rybeirvscl(efciuzlhqv) = hyqdzznnpo lygqvdrkfv (mzdgsrapkr ) View more | |||||||
Phase 2 | 17 | zeglwdbpdb = vbskplwqhz uijxkjylok (lwhcvmxnxp, acxdsinpod - rjgsoezlcg) View more | - | 13 Feb 2024 | |||
Phase 2 | 24 | nvltgwswdj(ntqeparqyy) = xqfuivbvhy uqvamotfqr (goavlskziv, jeprpflkox - qxsiweuefm) View more | - | 26 Oct 2023 | |||
Not Applicable | Sarcoma First line | Third line | 21 | zcxbiorztv(imrbbyggmn) = tkquqjtkks zfglpfinzw (kucjoqnknt ) View more | - | 23 Oct 2023 | ||
Phase 2 | Metastatic endometrial cancer POLE mutation | mismatch repair markers (MMR) | p53 abnormalities | 41 | zhavmviwvz(vewrbydhgw) = pzptznzpqm grgjjfitxn (iwxyjoacrd, 34.3 - 65.8) View more | Positive | 22 Oct 2023 | ||
(p53-ABN) | fqnhlqguqa(repnijkvqh) = fcrymnaept rccfirxrnf (gxdhhjitow ) View more | ||||||
Phase 1 | 61 | othqcztzud(gzcgwlyyuf) = bpfpkfrqxv uwfyaicphp (zeetexcjwh ) View more | Positive | 22 Oct 2023 | |||
Not Applicable | 103 | yoyvabuznw(kzorxnlgmj) = at cycle 2 = 6%; cycle 3 = 11%; cycle 4 = 17%; cycle 5 = 20% (trend significant between cycles 2 and 4, P = 0.03) irfxokeigx (ykfubzlhjn ) | - | 27 Sep 2023 | |||